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ABSTRACT 
 
 Reovirus, which belongs to the Reoviridae family, is a non-enveloped, 
dsRNA viruse.  Known to infect a wide range of hosts including humans, this 
virus is generally asymptomatic, and a majority of the population expresses anti-
reoviurs antibodies from exposure during childhood.  Within the last 70 years, 
this seemingly obscure virus has gained significant attention as a possible 
oncolytic virus, which as a group possess a number of qualities that make them 
theoretically ideal as cancer therapeutics.  Namely, they are both safe and well 
tolerated, and specifically infect and destroy malignant cells.  Theorizing that 
reovirus type-3 dearing would selectively infect and mediate cell death in ras 
activated cells, researchers have attempted to exploit this non-attenuated strain 
as an oncolytic virus.  By analyzing pre-clinical and clinical studies of reovirus, 
both as a monotherapy and as part of a variety of combination therapies, I show 
that reovirus therapy is both safe and well tolerated, but with poorly understood 
efficacy.  Further work is required to elucidate the mechanism behind reovirus 
mediated oncolysis, to fully maximize its oncolytic potential. 
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Introduction 
 
Viruses harbor a number of unique characteristics that lend them great 
potential as oncolytic agents.  The ability to overcome and evade a host’s 
immune system and corrupt a host’s cellular mechanics has led to crucial 
implications in cancer research.  It has been found that some, including the 
Human Papilloma Virus (HPV) and Epstein Barr Virus (EBV), act as cancer 
causing agents.  In fact, it is estimated that viruses are the cause of 20% of 
human cancers.  Inversely, it has also been theorized and recently shown that 
viruses may also be used as oncolytic agents as part of cancer treatment.      
It has only been within the last half century that we have become aware of 
some of these oncolytic capabilities, and as it stands today, there has only been 
limited success in utilizing them.  Demand for these novel oncolytic agents, 
however, only continues to grow.  Despite the considerable progress in cancer 
therapy, cancer is still the leading cause of death worldwide according the World 
Health Organization (WHO) at 13% or 7.6 million deaths in 2008.1   
Viruses offer a novel approach to one of the world’s greatest health 
concerns.  Through evolution, viruses have naturally acquired the abilities to 
selectively infect cells and corrupt and even destroy them.   The basis for 
oncolytic viruses is to utilize viruses that selectively infect and destroy tumor 
cells, thereby eliminating the cancer and leaving the host cells unaffected.  If 
2 
successful, it has the potential to offer a systemically selective therapeutic 
approach to a wide variety of different cancer types.   
 
A. History of Cancer Therapy 
 
Prior to the twentieth century, cancer therapy was synonymous with 
surgery.  Even so, it was not until 1846 with the introduction of anesthesia that 
allowed surgery to begin to advance itself as a successful cancer therapy (Kelly, 
Russell).  Through time, surgery has improved in numerous ways including 
becoming more aseptic and being able to reach less accessible regions, but still 
relies on the cancer being localized, which in turn relies on early detection.  Once 
a cancer spreads past the primary tumor and to the lymph nodes and beyond, 
the success rate for surgery, even today, is markedly decreased.  
As such, a variety of different approaches have been pioneered including 
what we now know as radiotherapy, chemotherapy and immunotherapy.  In 
1895, Wilhelm Conrad Röntgen discovered X-rays followed, a few months later, 
by the discovery of natural radioactivity by Henry Becquerel.2  These two 
discoveries would pave the way for Emil Grubbé’s first use of radiotherapy on an 
ulcerated breast cancer in January 1896 in Chicago.  For the next forty years, 
surgery would cede its place as the primary cancer therapy to radiotherapy for a 
majority of cancers, but ultimately radiotherapy failed to substantially improve the 
life expectancy in malignant disease prior to the mid twentieth century.3  It would 
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take until the 1950’s and the development of assays to quantitate in vitro and in 
vivo cell killing and thereby lead to the establishment of therapeutic indexes for 
radiotherapy.2  Therapeutic indexes describe the difference in dosages required 
to achieve therapeutic effects versus the dosages that cause toxicity.  A large 
therapeutic index is desirable so that there is a greater separation between the 
dosages that have therapeutic effects and those that cause negative side effects 
(toxicities) so as to not cause any side effects at all. Unfortunately, even today, 
the therapeutic index for radiotherapy is usually smaller than desired due to the 
unspecific and harmful nature of the various energy waves used.  This means 
that in a normal therapeutic regimen, a majority of patients will experience 
negative toxicities which then must be weighed against the treatment’s 
therapeutic value.  This is less than ideal.       
Chemotherapy, which began with the invention of the folic acid antagonist 
4-aminopteroyl-glutamic acid (aminopterin) in 1946 for use against leukemia, 
also had its own limitations.3  Despite aminopterin and the successors it inspired 
being fairly successful therapeutics against blood based cancers like leukemia, 
solid tumor cancers were only marginally affected.4  Additionally, aminopterin 
was implicated in numerous fetal defects as early as 1952.5  It would later 
become clear that aminopterin had significant teratogenic effects, which limited 
its usage.  Even with the addition of steroids and nucleic acid antagonists, it 
became clear that chemotherapy, like radiotherapy, would not be a silver bullet 
against cancer. 
4 
B. History of Oncolytic Viruses 
 
It is unclear as to specifically when viruses were discovered, but many 
point to Martinus Beijernick’s 1898 study of an organism that he termed a 
contagium vivium fluidium, which was able to be filtered through a Chamberland 
candle (bacteria cannot pass through) and still cause the tobacco mosaic 
disease.6  Just under 20 years later, in 1917, viral particular nature would be 
proven with the invention of the plaque assay, and in 1939, the first pictures of 
viral particles were captured with an electron microscope.3 
Interestingly, viraltherapy (or the use of oncolytic viruses as cancer 
treatment) came prior to the discovery that viruses could cause cancer.  Figure 1 
shows a timeline comparing major markers in cancer therapy with major markers 
in virology, which converge to what is now considered modern viraltherapy.  
Coinciding with the gradual discovery of viruses at the start of the twentieth 
century, a number of case reports were published that showed that various 
diseases, with known virus etiology, could cause the temporary regression of 
tumors under certain conditions; namely the patient being younger in age and the 
cancer being either a leukemia or lymphoma.7  These conditions were often 
associated with a tumor induced immune deficiency and remission would 
generally only last one to two months.3   
It was not until the 1950’s and 1960’s, with the advent of cell culture 
techniques and the ability to propagate and purify viruses, that clinical  
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Figure 1: Milestones in Cancer Therapy and Virology 
This figure illustrates the cornerstone accomplishments in both cancer therapy 
and virology and compares them chronologically.  The endpoint is the first 
approved oncolytic virus, Adenovirus H101.3 
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virotherapy began to take shape.  Since then, clinical trials have been performed 
using Hepatitis virus, West Nile virus, Mumps virus, Coxsackie virus, Herpes 
virus, Vaccinia virus, Reovirus, and Adenovirus among others.  Four significant 
clinical trials between 1949 and 1974 in particular set the stage for the first 
approved oncolytic virus in 2005 as shown in Table 1.  In 1949, Hepatitis B virus 
was used to treat 22 patients with Hodgkin’s disease: 7/22 improved in clinical 
aspect, 4/22 showed reduced tumor size.  Then in 1952, Egypt 101 virus (early 
West Nile) was used to treat 34 patients with advanced neoplastic disease: 14/34 
showed oncotropism and 4/34 showed tumor regression.  Four years later in 
1956, Adenovirus was used to treat 30 patients with cervical carcinomas: 26/40 
inoculations resulted in localized necrosis.  Finally, in 1974, Mumps virus was 
used to treat a variety of terminal cancers (gastric, pulmonary, and uterine being 
among the largest percent) in 90 patients: 37/90 showed greater than 50% tumor 
regression and 42/90 showed less than 50% tumor regression with only 11/90 
being unresponsive.3   
Unfortunately, many of these clinical trials, while outwardly positive, were 
also accompanied by a number of problems.  Similarly to the earlier reported 
case studies, these clinical trials demonstrated some of the same characteristics 
found earlier; the host often needed to be immunocompromised, otherwise, the 
host immune system would clear the virus and eliminate the oncolytic effect.  
However, in immunocompromised hosts, while they would show better oncolytic  
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Table 1: Early Viraltherapy – shows initial clinical trials of viral therapies 
attempting to suppress tumor growth.  Adapted from Kelly et al. 2007.3 
 
 
 
 
Year(s) Virus Disease No. of 
patients 
Administration Outcome Side effect 
1949 Hepatitis B 
virus
32
 
Hodgkin's 
disease 
22 Parenteral 
injection of 
unpurified 
human serum, 
tissue extract 
14/22 
developed 
hepatitis; 
7/22 
improved in 
clinical 
aspect of 
disease; 4/22 
reduction in 
tumor size 
Fever, malaise, 
death (1 
confirmed) 
1952 Egypt 101 
virus (early 
passage 
West 
Nile)
36
 
Advanced, 
unresponsiv
e neoplastic 
disease 
34 IV, 
intramuscular 
injection of 
bacteriologically 
sterile mouse 
brain, chick 
embryo, human 
tissue 
27/34 
infected; 
14/34 
oncotropism; 
4/34 
(transient) 
tumor 
regression 
Fever, malaise; 
mild 
encephalitis (2 
confirmed) 
1956 Adenovirus 
adenoidal-
pharyngeal
conjuctival 
virus 
(APC)
50
 
Cervical 
carcinoma 
30 IT, IA, IV 
injection of TC 
supernatant 
26/40 
inoculations 
resulted in 
localized 
necrosis 
Vaginal 
hemorrhage; 
infrequent 
(3/30) fever, 
malaise 
1974 Mumps 
virus (wild-
type, non-
attenuated)
5
6
 
Terminal 
cancers; 
gastric, 
pulmonary, 
uterine 
account for 
more than 
50% 
90 External post-
scarification; IT; 
IV; oral; rectal; 
inhalation of 
purified human 
saliva or TC 
supernatant 
37/90 
complete 
regression or 
decrease 
>50%; 42/90 
decrease 
<50% or 
growth 
suppression; 
11/90 
unresponsive 
7/90 adverse 
reactions: 
bleeding, fever 
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results, would also present with potentially deadly symptoms from the resultant 
infection that spread unopposed.  Therefore, on either side of the spectrum, 
researchers were left with problems on how to work around a host’s immune 
system. 
Once recombinant DNA technology became available in the early 1990’s, 
work picked up on modifying viruses to make them more selective, potent, and 
immunoregulative so that they could be used as successful oncolytic agents.  In 
2005, China approved the first oncolytic virus: a genetically modified adenovirus 
H101.8  Work today continues on developing and perfecting a number of different 
viruses, including reovirus, for use as oncolytic agents. 
These viruses are grown in permissive cell lines via multiple rounds of 
infection to propagate them.  They are in turn purified, characterized, and then 
administered.  The administration may occur through a number of different 
routes, each with its own unique characteristics.  Virus may be injected 
intratumorally (IT), intracavitally (IC), intravenously (IV), or intra-arterial (IA).  
Independent of administration route, the virus must reach the tumor and establish 
a lytic infection cycle as the primary basis of a successful oncolytic agent.  Viral 
selectivity for tumor cells is a key trait that allows the preservation of normal host 
cells and destruction of malignant cells during this process.   Secondarily, the 
virus should elicit a host immune response against infected malignant cells, 
increasing its therapeutic effect.  Ideally, the virus would be able to select for 
tumor cells systemically and lyse them while leaving normal tissue unaffected, 
9 
the idea being that a single administration could infect tumor cells even after 
metastasis to various places and eradicate malignant tissue.  However, research 
and clinical trials have indicated that such an ideal solution is far more difficult to 
achieve than to conceptualize. 
 As mentioned, a number of viruses beyond reovirus have been 
investigated with hopes to produce efficacious oncolytic agents.  Included in this 
group are Newcastle Disease Virus (NDV) and measles virus (rubeola), both of 
which are paramyxoviruses.  These are enveloped viruses with a negative sense 
single strand RNA (ssRNA) genome.  Given their sensitivity to interferon (IFN), 
which is in turn part of pro-apoptotic pathways, they were targeted early on in the 
1950’s and 60’s for use as oncolytic agents.7  Currently, both NDV and measles 
virus have undergone genetic modification for use as therapeutic oncoloytics.  
The measles virus has been attenuated and adapted to select for CD46 
receptors which are involved in compliment activation and thereby increase its 
tumor selectivity and oncolytic activity.9  By using reverse genetics, researchers 
were able to upregulate the highly fusogenic F protein in NDV and thereby show 
increased anti-tumor activity.10   Measels virus is currently in phase I clinical trials 
while NDV is in phase III clinical trials.7,11,12 
Herpes simplex is another virus that has garnered a significant amount of 
attention as a potential oncolytic agent since the late 1990’s due to the newfound 
recombinant DNA technology.3  It is a double stranded DNA (dsDNA) virus with a 
lipid envelope and icosahedral capsid.  By removing the gene for viral thymidine 
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kinase (TK), which is required for viral replication in non-dividing cells, it is 
believed that herpes simplex virus may act as an oncoloytic agent.7  Currently, 
Herpes simplex virus is in phase III clinical trials.13 
Similar to Herpes, vaccinia virus also displays potential as an oncolytic 
agent following a series of modifications.  A member of the poxvirus family, 
vaccinia virus has a linear, dsDNA genome and is enveloped.  It also contains its 
own RNA polymerase for cytoplasmic replication, a fairly unique feature for a 
DNA based virus.14  Like herpes simplex virus, a deletion of the TK gene grants 
vaccinia virus tumor selectivity and should theoretically increase its therapeutic 
index.7  Currently, vaccinia virus is in phase II clinical trials under the names 
Jennerex-594, vvDD-CDSR, and GL-ONC1.7   
 The most successful virus to date to be employed as a virotherapy is 
adenovirus.  It was identified in pre-clinical trials as a potential oncolytic in the 
early 1950’s, when it was known as adenoidal-pharngeal-conjuctival virus 
(APC).3  Adenovirus has a linear, dsDNA genome within an icosahedral capsid, 
without an envelope.7  More importantly, it has a number of innate safety features 
that lend to its potential as an oncolytic.  First, replication in quiescent cells is 
highly dependent on the inactivation of tumor-suppressor proteins by early virus 
proteins therefore deletion of those early viral protein genes renders the virus 
harmless to non-dividing cells.  Secondly, the gene E1a has total transcriptional 
control over all viral genes so replacing the E1a promoter with a tumor selective 
promoter also increases the virus’s theoretical therapeutic index.7,15,16  Working 
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from that theory, a new virus has been derived, based with a modified E1b gene 
(deleted) to induce p-53 mediated cell cycle arrest in normal cells harboring the 
virus leaving tumor cells susceptible.  While development started in the United 
States under the prototype name Onyx-15, the Chinese completed development 
once the Americans halted the program and succeeded in gaining approval for 
the first virotherapy, Adenovirus H101.8 
 
C. Reovirus Family and Structure 
 
Orthoreovovirus (simply called reovirus here) belongs to the Reoviridae 
family which is characterized by viruses with a double stranded (ds) RNA 
genome that contain 9-12 segments.14  Reoviridae are known to infect a wide 
range of eukaryotic hosts, ranging from mammals to plants.  Four of the nine 
genera within the Reoviridae family infect humans: Reovirus, Orbivirus, 
Rotavirus, and Coltivirus.   
Reovirus, or Respiratory Enteric Orphan Virus, was initially isolated from 
respiratory and gastrointestinal (GI) tracts and was not associated with any 
known disease state.  Infectious reovirus particles are generally 70-85 nm and 
are non-enveloped. Viral proteins are arranged in two concentric icosahedral 
capsids, which contain ten segments of discrete dsRNA, and act as the 
production site for viral mRNAs.14  
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Figure 2: Reovirus Capsids and Cores 
Reovirus virion, ISVP, and core particles shown with color applied for clarity.  
Structures were obtained from transmission cryoelectron microscopy and 3-D 
image reconstruction.  Used with permission from Chandran et al. (2002).17  
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The outer capsid shell is composed primarily of the μ1 and σ3 proteins, with one 
σ1 protein located at each of the capsid’s 12 vertices that serves as the viral 
attachment protein (Figure 2).17,18,19 Reovirus σ1 is a trimeric molecule whose C-
terminal heads bind to junctional adhesion molecule-A (JAM-A) to mediate viral 
entry.20,21  Interestingly, reovirus σ1 is remarkably structurally similar to another 
oncolytic virus protein, adenovirus attachment protein fibre.22  The inner core 
capsid is composed primarily of four proteins: λ1, σ2, λ3, and μ2 with another 
protein, λ2, spanning the inner and outer capsid.14,19   
During infection, reovirus undergoes sequential loss of capsid proteins via 
proteolytic conversion by pancreatic proteases, which is necessary to produce 
infectious subviral particles (ISVPs) and cores.17,23  These ISVPs are the primary 
form of reovirus found in early (<8 hours) infection sites.14  ISVPs lack σ3 while 
cores lack both σ3 and μ1.17  Following entry into the host, reovirus proceeds 
along a normal pattern of viral pathogenesis; replicating, spreading throughout 
host tissue, inducing a host immune response, causing cell injury, and persisting 
until the host immune response is able to clear it.14    
Anti-reovirus antibody surveys conducted to determine reovirus 
epidemiology show that a majority of adults, despite differences in geography 
and cultural settings, have detectable antibodies for all three serotypes 
(represented by protype strains type 1 Lang [T1L], type 2 Jones [T2J], and type 3 
Dearing [T3D]) .14  More specifically, a study done by Children’s Hospital in 
Boston found that from one to three years of age, the incidence of anti-reovirus 
14 
antibodies went from 25% to >70%.24  Since reovirus is capable of infecting all 
types of mammals, it is unclear how the viral reservoir and human population 
interact.  What is certain is that a majority of the human population worldwide 
contain antibodies for all three serotypes of reovirus, a fact that must be 
considered when evaluating reovirus as an oncolytic agent. 
 
D. Reovirus Induced Apoptosis 
 
Apoptosis is a process in which a cell, for various reasons, will commit 
suicide.  It is done as a last resort, to prevent further dissemination of harmful 
materials; viral, genetic, or other.  In viral infections, apoptosis occurs once a 
virus has managed to bypass both the innate and adaptive immune system as 
well as a cell’s cytoplasmic defense mechanisms.  From there, a number of 
different mechanisms may be employed to cause apoptosis.    
As of today, the mechanisms behind reovirus induced apoptosis are still 
largely unclear.  A number of different pathways have been implicated in the 
process, and it can be shown that certain actions can either up or down regulate 
apoptosis, but exactly how each pathway works is, as of yet, unknown.     
Reovirus induced apoptosis is believed to be directly proportional to viral 
entry efficiency, which in turn is thought to be determined by two genes.  The first 
gene responsible for reovirus entry is termed the S1 gene, which encodes the σ1 
attachment protein.20,25,26  The M2 gene which encodes the μ1 protein is also 
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believed to influence apoptosis.27  While the actual events that lead to host cell 
apoptosis may be independent of these two viral proteins, the overall ability of 
reovirus to induce apoptosis is correlated to these two proteins.  Since they are 
known to function during reovirus entry, it can be implied that the events that 
transpire during reovirus entry impact apoptosis. 
Further research has indicated that interferon regulatory factor 3 (IRF-3) 
and nuclear factor kappa B (NF-κB) are required for apoptosis in reovirus 
infected cells.28,29  A number of different stimuli may activate NF-κB, including 
tumor necrosis factor alpha (TNF-α), interleukin-1, and lipopolysaccharide.30  
Together, IRF-3 and NF-κB are known to induce the formation of a number of 
different gene products, including beta interferon (IFN-β) .31  It was, for a time, 
believed that IFN-β was responsible for mediating apoptosis via one of the many 
IFN-stimulated genes (ISGs) in reovirus infected cells, but further research has 
revealed that the process is IFN independent.  Instead, it is possible that another 
protein in the B-cell lymphoma 2 (Bcl-2) family, Noxa is responsible for inducing 
apoptosis.32  This seems logical because Noxa is pro-apoptotic, and therefore it 
would be a likely target to induce apoptosis.  Interestingly, overexpression of Bcl-
2 itself, which is anti-apoptotic, had previously been shown to block reovirus 
apoptosis, but not growth in Madin-Darby canine kidney (MDCK) cells.25 
There could just as well be a myriad of other factors that are associated 
with reovirus induced apoptosis.  For example, protein kinase R (PKR), which is 
also an ISG, is activated by dsRNA in the cytoplasm of host cells.  This in turn 
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causes the activation of eukaryotic initiation factor 2 (eIF2α) which blocks 
translation initiation.33  However, after sustained activation, PKR is also known to 
promote apoptosis.33  So if reovirus is able to activate PKR, whether directly due 
to the virus’s dsRNA presence in the cytoplasm or another means, it would then 
be able to promote apoptosis.  Another enzyme, 2’-5’ oligoadenylate synthase 
(2’5’OAS), may also be activated by the same factors that cause PKR activation 
(dsRNA in cytoplasm).  It works to produce 2’-5’ adenylic acid from ATP which 
then activates RNase L that degrades dsRNA.34  The resultant RNA fragments 
then go on to signal a variety of other molecules and may also result in 
apoptosis.  It has also been found that other pathways, such as interferon 
induced Daxx upregulation and JAM-A independent/antibody mediated uptake in 
reovirus both contribute to reovirus induced apoptosis.35,36  In total, there are a 
number of ways that reovirus may be causing apoptosis, and to fully appreciate 
its potential as an oncoyltic agent, it will be important moving forward to elucidate 
these mechanisms. 
 
Results: Reovirus as an Oncolytic Agent 
 
 This section will describe the process that has led to reovirus being at the 
forefront of potential viraltherapeutics.  To be able to utilize reovirus as an 
oncolytic agent, it was first researched to see if it possessed the general criteria 
for an oncolytic virus.  Namely, it must i) be able to infect and destroy tumor cells 
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specifically and ii) the resultant infection and/or disease must not negatively 
affect the patient beyond what the initial cancer could do.  Beyond that, there are 
a number of other factors that researchers have, and continue to, evaluate 
reovirus therapy on.  First, is the method of administration.  Theoretically, an IV 
route that is systemic would be ideal because that would expose all tumors 
including those that have undergone metastasis and may not have been 
detected.  Even an IT route, although not as direct, should also yield systemic 
viral exposure if a successful infection is established.  The disadvantage to this 
model is that it is unclear how the host immune system and any modifications to 
the immune system that could be made in combination therapy would affect 
reovirus therapy.  For example, it could be that IV administration in an immune 
competent patient previously exposed to reovirus would not yield a successful 
infection in cancer cells due to viral immune clearance.  Simultaneously, it is also 
possible that viral immune targeting is a vital component of reovirus induced 
oncolysis. While reovirus as an oncolytic has a number of potential upsides, such 
as the ability to be efficacious in a systemic manner, how the immune system, 
pre-exposure, and resistance to reovirus are all questions that must be closely 
considered in attempting to utilize reovirus as an oncolytic agent.    
Reovirus has undergone testing in pre-clinical models to determine its 
effectiveness as an oncolytic virus against any possible cancers and to attempt 
to elucidate the mechanism behind its tumorgeneic selectivity.  Once it was 
shown that it had successfully treated malignant disease within animal models, 
18 
the virus would have to move through phase I-III clinical testing.  Phase I clinical 
testing establishes drug efficacy and is based on pre-clinical studies.  Phase II 
clinical testing is used to maximum dosage levels and looks for any potential 
toxicities or negative side effects.  Phase III clinical testing, which incorporates 
the largest number of patients, looks to continue establishing the virus’s efficacy 
as well as attempts to uncover any potential rare adverse effects.  Should the 
virus pass through phase III clinical trials, it would join Adenovirus H101 as part 
of the burgeoning viraltherapy regimen. 
 
A. Pre-Clinical Testing of Reovirus 
 
The first real break in establishing reovirus as an oncolytic agent beyond 
theory occurred in 1993, when it was realized that murine cell lines lacking 
endogenous epidermal growth factor receptors (EGFR) were resistant to reovirus 
infection.37  It had previously been shown that sialic acid was necessary for 
reovirus attachment.  Using cells treated with neuraminidase, which removes cell 
surface sialic acid residues, it was shown that this modification significantly 
prevented reovirus attachement.38,39  However, many cell plasma membrane 
glycsialyated so that alone did little to specify which recptors or factors were 
conferring susceptibility to reovirus infection.  Confirming that EGFR, which is 
implicated in numerous pro-malignant pathways, was increasing cellular reovirus 
susceptibility shed light on the possibility of using reovirus as an oncolytic agent.  
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Following that, a number of important preclinical studies have been performed in 
an attempt to determine the potential efficacy of reovirus mediated oncolysis. 
 The first such study was done by Strong and Lee (1996) who looked at the 
ability of the oncogene v-erbB, which contains an EGFR homologue, to confer 
susceptibility to reovirus infection in cells that did not previously exhibit significant 
levels of susceptibility.40  To do so, the authors utilized NIH 3T3 cells which are 
poorly susceptible to reovirus and NIH 3T3 transformed cells with the v-erbB 
oncogene (transformed cells were renamed THC-11).  They then infected both 
cell types with reovirus at a multiplicity of infection (MOI) of approximately 10 
plaque forming units (PFU) per cell.  Immunofluorescence microscopy was used 
to assess infection (Figure 3).  While NIH 3T3 cells showed little susceptibility to 
infection as expected, THC-11 cells demonstrated significantly elevated levels of 
reovirus infection.  Further study utilizing sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) to assess viral protein levels revealed that 
THC-11 cells contained much greater levels of viral proteins 12-48 hours post-
infection relative to NIH 3T3 cells.  This supports the idea that THC-11 cells 
became more susceptible to reovirus infection.  The authors additionally tested 
lysates from harvested infected cells and found an approximately 13 fold higher 
viral output from THC-11 cells.  Taken as a whole, this study was one of the first 
to suggest that reovirus infection utilized an already activated signaling pathway 
that either resulted in or was the result of an up-regulation of EGFR.   
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Figure 3: Immunoflourescence assay of viral proteins expressed in 
reovirus-infected NIH 3T3 and THC-11 cells.   
 
This figure shows that NIH 3T3 cells are poorly susceptible to reovirus infection 
while THC-11 cells that have been transformed with the v-erbB oncogene (EGFR 
homologue) are susceptible to reoviurs infection.  Cells were infected with an 
estimated multiplicity of infection (MOI) of 10 PFU per cell.  At 48 hours 
postinfection, cells were fixed, processed, and reacted with rabbit anti-reovirus 
type 3 antibody and then with fluorescein isothiocyanate-conjugated goat anti-
rabbit immunoglobulin G.  The magnification for all picutres is x132.  (A) 
Uninfected NIH 3T3 cells.  (B)  Unifected THC-11 cells. (C) Infected NIH 3T3 
cells. (D) Infected THC-11 cells.  Reproduced with permission from Strong et. al. 
(1998).41 
 
Another important pre-clinical study of reovirus oncolysis was Strong et al.’s 
(1998) work that built from the previous research on v-erbB and demonstrated 
how Ras activation confers reoviurs infection susceptibility in NIH 3T3 cells.41  
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Using a panel of NIH 3T3 transformed cells, with a number of activated 
oncogenes downstream of EGFR, both Sos and Ras transformations conferred 
susceptibility to reovirus.  They also found that viral transcripts were generated in 
non-susceptible cells, but then were not further translated.  This suggested that 
while reovirus was able to gain entry into the host cell, there was a translational 
control preventing further infection.  It was then shown that PKR, which inhibits 
translation when phosphorylated, was phosphorylated in non-susceptible cells, 
but not in the Ras activated cells.  Additionally, when 2-aminopurine was added 
(acts as an inhibitor or PKR phosphorylation) or the PKR gene was deleted, 
reovirus protein synthesis (translation) was drastically increased.  Since Ras 
inhibits PKR phosphorylation, the authors proposed that the Ras-PKR 
mechanism was responsible for reovirus oncolysis (Figure 4).  While newer 
results bring this proposed mechanism into question, it none-the-less sets the 
stage for further pre-clinical and clinical trials of reovirus as an oncolytic agent.  
 Following Strong et al. (1998), another landmark pre-clinical study by 
Coffey et al. (1998) was published that demonstrated reovirus oncolytic activity in 
solid tumors using murine xenograft models.41,42  To do so, the authors utilized v-
erbB transformed NIH 3T3 cells and human glioblastoma U87 cells for the study.  
Both of these cell types had previously been shown to be susceptible to reovirus 
infection in vitro (v-erbB transformed NIH 3T3 cells had been renamed THC-11 
cells as discussed previously) .41  Tumors were grown in severe combined 
immunodeficiency (SCID) mice and then received an IT injection with 1.0 x 107  
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Figure 4: Proposed Reovirus Mechanism of Infection  
 
Reovirus infection is dependent on Ras pathway activation.  Ras inhibits PKR 
which would otherwise phosphorylate eIF-2a that prevents viral replication and 
transmission (Adapted from Norman et al. 2002).43  
 
PFU of reovirus.  Ultravioloet (UV) inactivated virus was used as a control.  
Reovirus injection was shown to significantly reduce the size of tumors in both 
cell line models, while UV inactivated virus injections had no effect on tumor size.  
This study went further and attempted to understand the effect of a host immune 
system and the role it may play in reovirus oncolysis, something that the SCID 
mouse model is inherently unable to do.  For this, the authors elected to use Ras 
transformed C3H-10T112 fibroblasts grown in immune competent C3H mice.  
Reovirus administrated was altered from a single IT injection to a series of 6 IT 
injections at 1 x 108 PFU each day for 9 days followed by a single IT injection at 
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1 x 107 PFU every 2 days for 12 days.  This was done in hopes to sustain 
reoviurs infection in the face of a competent immune system, but not go as far as 
to kill the animal with the virus itself.  Like the previous experiment, UV 
inactivated virus was used as a control.  Tumor regression occurred in 6 of 9 
mice (67%) tested.  Additionally, the same experiment was performed on mice 
pre-challenged with reovirus to determine if pre-existing antibodies (Abs) would 
affect tumor susceptibility to reovirus infection, especially given the high levels of 
reovirus exposure in the human population.  Previous exposure had no effect on 
revirus oncolysis in the murine models tested.  This study was therefore the first 
to show that reovirus could be used successfully against solid tumors in animal 
models.  
 Next, Wilcox et al. (2001) published a critical study on reovirus’s efficacy 
against human experimental malignant gliomas.44  Both SCID NOD mice and 
immune competent CD-1 nude mice were utilized due to the severe toxicity of 
reovirus in SCID models, especially involving nueral cells.  Tumors were grown in 
their murine hosts for 2-3 weeks until palpable, then received a single IT injection 
of 1 x 107 PFU of reovirus.  UV inactivated virus was used as a control.  Both 
subcutaneous and intracranial tumors were modeled for this study.  Previous in 
vitro results showed reovirus was able to infect 20 of the 24 (83%) established 
malignant glioma cell lines used, and in those infected, there was almost 
complete cell death 72 hours post exposure to reovirus.  In vivo subcutaneous 
models of two malignant glioma cell lines, using only the SCID NOD mice, 
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showed that reovirus was able to dramatically reduce tumor size (1.49 cm2 – 
untreated compared to 0.11 cm2 – treated).  However, the SCID NOD mice 
treated with reovirus developed severe infections.  A majority of these infections 
resulted in necrosis of hind limbs.  In vivo intracranial models using the same two 
malignant glioma cell lines as in subcutaneous models, and modeled in both 
SCID NOD and CD-1 nude mice, found a significant reduction in tumor mass.  
Furthermore, CD-1 nude mice demonstrated a longer lifespan and regained more 
body weight relative to UV inactivated virus treated animals.  Reovirus was then 
tested against 16 ex vivo brain tumor surgical specimens including 4 
glioblastoma multiforms, 3 anaplastic astrocytomas, one astrocytoma, and seven 
menigiomas.  Reovirus exposure resulted in 9 out of 9 (100%) cell death in 
primary glioma specimens but had no effect on meningioma specimens, 0 out of 
7 (0%).  Based on the obtained data, the authors suggested reovirus (brand 
name Reolysin ®) be started in phase I clinical testing as a potential therapy for 
malignant gliomas.   
 Alain et al. (2002) published the results of another important pre-clinical 
study that sought to determine the potential efficacy of reovirus treatment of 
lymphoid malignancies.45  This study was divided into two parts, the first being an 
in vitro/ex vivo study which looked at the susceptibility of nine lymphoid cell lines, 
27 primary human lymphoid malignancies, and a variety of normal lymphocytes 
to reovirus infection.  The normal lymphocytes were included to show reovirus 
selectivity in a systemic application.  Additionally, SCID NOD mice xenograft 
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models of malignant lymphoids were also tested for susceptibility to reovirus 
mediated oncolysis.  The authors found that Burkitt lymphoma cell lines Raji and 
CA46 were susceptible while Daudi, Ramos, and ST486 cell lines were not 
susceptible to reovirus infection.  Also, all diffuse large B cell lines (OCY-LY1, 
OCY-LY2, OCY-LY8, and OCY-LY10) that were tested were found to be 
susceptible.  Each susceptible cell line found displayed reduced viability, cell 
clumping, loss of shape, and a granular phenotype consistent with cytopathic 
effects.  Then, Daudi and Raji cell lines were utilized in the SCID NOD xenograft 
models and treated with a single IV injection of reovirus between 1 x 107 and 5 x 
107 PFU.  Just as in the in vitro studies, only Raji models showed reovirus 
infection and oncolysis via reduced tumor size.  Of the 27 primary human 
lymphoid malignancy samples tested, all B-cell CLL samples, 1 follicular NHL 
sample, 1 lymphocytic NHL sample, 1 mantle cell sample, 1 Burkitt lymphoma 
sample, and 2 diffuse B-cell samples were found to be susceptible to reovirus 
infection.  However, no normal lymphocytes or progenitor cells were found to be 
susceptible.  This indicates again, that reovirus has selective oncolytic effects in 
that it targets tumor cells for reovirus mediated oncolysis, but is unable to infect 
normal cells.  Taken together, this data suggests the use of reovirus as a 
potential therapeutic agent against lymphoid malignancies.  
 Another study published the same year, by Normal et al. (2002), 
demonstrated the potential for reovirus to be used as an oncolytic agent against 
human breast cancer.43  Despite the fact that an activating ras mutations are only 
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infrequently found in breast cancer, there is a large amount of evidence that ras 
signaling serves as an important step in the progression of breast cancer.46  
Believing that ras status was implicated in both susceptibility to reovirus infection 
and breast cancer progression, the authors opted to attempt to utilize reovirus 
against breast cancer.  One of the key rationales in doing this study was the 
additional fact that Her-2, a member of the EGFR family which had previously 
been shown to mediate reovirus infection, is overexpressed and amplified in 
approximately 30% of breast cancer cells.47,48  Through in vitro studies, the 
authors were able to show that reovirus was capable of infecting a panel of 
breast cancer cell lines while having no effect on cells of normal breast 
epithelium.  Susceptible cells showed characteristics of cytopathic effects, and 
reovirus proteins were significantly elevated >20 hours postinfection.  Then, 
using SCID NOD xenograft murine models, the authors showed not only 
oncolytic activity against a tumor following a single IT injection of 1 x 107 PFU, 
but also that tumors distant from the primary tumor (orthotropic models) also 
displayed signs of reovirus mediated oncolysis when reovirus was administered 
IV at the same dose.  When sampled, researchers were able to obtain replication 
competent virus from all tumors where oncolytic activity was documented.  This 
data represents not only a potential use for reovirus as an oncolytic therapy 
against breast cancer, but also suggests that it could work to affect secondary 
tumors that have undergone metastasis and are distant from the primary tumor.  
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Such a therapy would be ground breaking, and is one of the major theoretical 
benefits of oncolytic viraltherapuetics. 
 To further elucidate the cellular mechanisms that reovirus utilizes to 
mediate cell death, Norman et al. (2004) published another study that focused on 
determining what signaling elements beyond the hypothesized ras/PKR 
mechanism were being used by reovirus to mediate infection.49  Using a panel of 
NIH 3T3 cells consistent with previous studies, various ras-activated mutants 
were generated, and then tested for susceptibility to reovirus infection.  The 
purpose of the design was to elucidate what potential downstream events of ras 
activation were functioning in reovirus mediated oncolysis.  It was found that 
reovirus replication and oncolysis was independent from either raf or 
phosphatidylinositol-3-kinase (PI-3) signaling, both of which are downstream of 
ras.  However, RalGEF signaling rendered NIH 3T3 cells susceptible to reovirus 
infection.  It was thought from previous research that RalGEF had the potential to 
activate a number of different effectors, including stress activated protein kinases 
(JNK) as well as p38.50,51  Both JNK and p38 were subsequently examined and 
the authors found that reovirus replication was dependent on p38 kinase but not 
JNK.  These results implicate RalGEF and p38, as downstream elements in the 
proposed ras/PRK model, as additional pathway elements that contribute to 
reovirus mediated oncolysis.  However, it should be noted that there are still 
significant gaps in the present understanding of these mechanisms.  Both ras 
and RalGEF are thought to signal to a great number of effectors beyond just 
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p38/JNK meaning, that while this study presents an interesting correlation, it is 
far from conclusive.   
 In a recent pre-clinical study by Twigger et al. (2012), new data suggests a 
potentially more complicated picture of reovirus mediated oncolysis.  To 
determine the ability of reovirus to act as a viraltherapeutic in cases involving 
head and neck cancers, revirus susceptibility was measured in 15 head and neck 
cancer cell lines.  Furthermore, pre and post entry events were also studied in 
two of the least and most susceptible cell lines to further elucidate the 
mechanisms underlying cellular susceptibility and resistance to reovirus.  It was 
found that JAM-1 expression, which is thought to mediate reovirus cellular entry, 
was not correlated to susceptibility to reovirus induced cell death.  Also, the 
generation of ISVPs prior to cell entry was also found to not impact susceptibility 
as previously hypothesized.  Most strikingly, the authors found that there was no 
significant correlation between ras activation status and susceptibility to reovirus 
infection.  Additionally, PKR inhibition (by phosphorylation), or the lack thereof, 
did not alter the oncolytic effect of reovirus.  This data runs against the previously 
reported data and suggests that the mechanism behind reovirus oncolytic activity 
is much less clearly defined than the ras/PRK model would indicate.  So while 
this study did show that reovirus has potential as a viraltherapeutic against a 
variety of head and neck cancers, there are as of yet, no clear biomarkers to 
predict reovirus susceptibility.  If these results are not isolated to only head and 
neck cancer cell lines, they would demonstrate that the ras activation model 
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thought to dictate reovirus selectivity and oncolytic properties should be 
reexamined.                
 As it has become clear that reovirus therapy will likely be used in 
combination with other cancer therapeutics, researchers have set out to 
understand potential synergies of select combinations in both pre-clinical and 
clinical studies.  An important study into this matter was recently published by 
Pan et al. (2013) which dealt with the use of chemotherapeutics that activate 
p53.53  Building off previous research which showed that p53 stabilization would 
enhance reovirus induced apoptosis, researchers sought to find out if activation 
of p53 by chemotherapeutics used in combination with reovirus would similarly 
enhance reovirus oncolysis.54  For this study, reovirus was combined with 
actinomysin D (ActD), etopside (Etp), and doxorubicin (Dox); all of which are 
topoisomerase II inhibitors.  Both ActD and Etp greatly increased reovirus 
apoptosis in p53 +/+ cell while p53 -/- cells were unaffected relative to reovirus 
monotherapy.  Dox and reovirus treated cells did not show a significant increase 
in reovirus induced apoptosis.  In addition, many p53 target genes were also 
found to be upregulated when reovirus was combined with ActD or Etp including 
p21 and bax.  Both p21 and bax were shown to be upregulated directly in 
proportion to the effect of p53 on increasing reovirus induced apoptosis.  Another 
p53 effector, NF-κB, also showed an induced activation when treated with ActD 
or Etp.  This too increased cell death by reovirus induced apoptosis.  Data from 
this study suggests a number of different things.  First, it again suggests that 
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there is much more than simply the ras/PKR model behind reovirus oncolysis.  
Also, this paper suggests continued research in increasing reovirus efficacy by 
combining it with other therapeutics.  Lastly, it indicates that it will be critical to 
understand what biomarkers clinicians and researchers should be looking for to 
determine appropriate use of reovirus.  As of yet, neither ras nor p53 status has 
had any clinical significance in regards to reovirus therapy.  Understanding these 
biomarkers will play an important role moving forward.       
 
B. Phase I Clinical Trials 
 
Most clinical trials have, and currently are using Reolysin ®, the 
proprietary name for Oncolytic Biotech’s wild type reovirus (serotype Dearing).  
While it entered clinical use as part of phase I studies in early 2000s, it has yet to 
be approved by the FDA.  As a wild type virus, Reolysin ® and reovirus as 
referred to in the pre-clinical section are interchangeable.  So while early phase I 
studies refer to their compound as reovirus, it is important to understand that 
there is no distinguishing formulation between the two. 
In one of the first phase I clinical trials, Forysth et al. (2008) sought to 
determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of 
IT administered reovirus in the treatment of recurrent malignant gliomas.55  
Twelve adult patients (age > 18) were enrolled with a median age of 53.5 years.  
All patients had received prior radiotherapy with or without chemotherapy.  The 
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median time of reovirus administration following diagnosis with malignant gliomas 
was approximately twelve months.  Reovirus was administered IT stereotactically 
at single dosages of 1 x 107, 1 x 108, and 1 x 109 tissue culture infectious dose 
(TCID50).  It was found that the MTD was not reached.  None of the adverse 
effects (AE), even at the highest concentration of 1 x 109 TCID50, were definitely 
or probably related to the administration of reovirus therapy.  Out of the twelve 
patients, 10 patients had tumor progression, one had stabilization, and one was 
not evaluable for response.  However, despite these results, it should be noted 
that the study was not designed to test the efficacy or reovirus monotherapy.  
Therefore, as the authors note, any benefits could be due to patient selection or 
other variables outside of reovirus oncolysis.  Overall, the study was considered 
a success and marked the first time a non-attenuated (wild type) virus had been 
injected into brain tissue to act as an oncolytic agent with no probable AE. 
Vidal et al. (2008) reported on another phase I clinical trial that tested daily 
IV Reolysin ® administration on 33 adult patients (age > 18) with advanced 
cancer.56  They sought to determine viral clearance by reverse transcription 
polymerase chain reaction (PCR) and antibody response by cytotoxicity 
neutralization assay.  Secondarily, they observed patients for viral tumor 
localization and replication as well as any anti-tumor activity associated with 
reovirus infection.  Reolysin ® was given in escalating doses as showin in Table 
2.  Based on the data obtained in the study, no DLT was established and they 
reported a MTD of 3 x 108 TCID50 only because that was the maximum available  
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Table 2: Dosage and Treatment Cycle in a Phase I Clinical Study with 
Reovirus Against Advanced Cancer 
 
This table shows the amount of each Reolysin® injection in TCID50 and the 
number of days per treatment cycle it was administered on.  The lowest dosage 
administered was 1 x 108 TCID50 while the largest was 3 x 10
10 TCID50.  The 
number of patients per cohort is also shown.56 
 
Cohort No. Dose (TCID50) Days Per Treatment 
Cycle 
Patients per 
Cohort 
1 1 x 108 1 3 
2 1 x 108 3 3 
3 1 x 108 5 4 
4 3 x 108 5 3 
5 1 x 109 5 3 
6 3 x 109 5 3 
7 1 x 1010 5 6 
8 3 x 1010 5 8 
 
amount of Reolysin.  Virus was found to be localized to tumor masses even after 
two weeks of evidence indicating a strong neutralizing anti-reovirus antibody 
(NARA) response.  The NARA response reached a peak level at 4 weeks post 
initial injection then became constant even in the face of escalating dosage of 
Reolysin ®.  This response is speculated to be one of the reasons no MTD could 
be established.  As a whole, this study demonstrated that reovirus (Reolysin ®) 
could be safely administered systemically at a dosage of 3 x 108 TCID50 each 
day and would localize and replicate only in tumor masses, possibly due to the 
NARA response. 
Thirukkumaran et al. (2010) described the potential for reoviurs use 
against prostate cancer, which ranks as the second deadliest cancer for US 
males.58  They found, both in in vitro and in vivo studies using murine models, 
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that reovirus could be used as an efficacious therapeutic to treat prostate cancer.  
For the in vitro study, three separate prostate cancer cell lines were shown to be 
susceptible to reovirus-induced oncolysis, while normal prostate epithelium was 
unaffected.  They also confirmed the presence of viral protein production by 
immunofloursecence and SDS-PAGE analysis and the occurrence of early 
mitotic events including phoshatidyl serine flipping by Annexin V binding, loss of 
mitochondrial transmembrane potential by Apo 2.7 staining, and DNA 
fragmentation by a PI incorporation assay.  A SCID NOD xenograft murine model 
was used for in vitro studies.  Reovirus was administered IT as a single dose at 1 
x 107 PFU once tumors were palpable and approximately 0.25 cm2 in size.  As in 
the in vitro study, all three prostate cancer cell line tumors regressed relative to 
controls (UV treated virus), with no virus found in tissue outside of the tumor.  
This data suggests that reovirus has significant potential as an alternative to the 
current treatment strategies for prostate cancer. 
To determine the safety and tolerability of combined reovirus and 
fractionated palliative radiotherapy, a dose-escalating phase I clinical trial was 
published by Harrington et al. (2010).59  Enrolling 23 adult patients (age > 18), 
each patient had advanced or metastatic solid tumors as follows: 8 melanoma, 3 
head and neck, 3 squamous cell carcinoma, 2 lung, 2 ovarian, 2 colorectal, 1 
esophageal, 1 pancreatic, and 1 unknown.  Patients were divided in to two 
primary groups; one low dose group which received 20Gy in 5 fractions (Phase 
1a) and 1 high dose group which received 36Gy in 12 fractions (Phase 1b).  
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Phase 1a was further divided into 3 cohorts, based on increasing dosage of 
reovirus (1 x 108 to 1 x 1010 TCID50) that was given on day 2 and 4 of a 28 day 
treatment cycle.  Phase 1b was divided into 3 cohorts as well, where each cohort 
received 1 x 1010 TCID50 of reovirus, but received additional dosages throughout 
the treatment cycle.  Reported AEs (< grade 3) included pyrexia, lymphopenia, 
influenza, flu-like symptoms, vomiting, erythema, diarrhea, fatigue, nausea, 
neutropenia, infection, and headache.  No DLT and therefore no MTD was 
established.  Tumor biopsies, when available, showed reovirus infection present.  
As in previous phase I studies, a maximum NARA response was seen at ~4 
weeks post initial injection and remained constant.  Patient response was 
measured in 7 patients each from phase 1a and b.  Of the phase 1a patients, 2 
had a partial remission (PR) and 5 achieved a stabilized disease (SD).  Phase 1 
b patients showed 5 had a PR and 2 achieved a SD.  This study showed that 
combined reovirus and radiotherapy was safe and warranted phase II clinical 
trials.  
Similar to the study combining reovirus with docetaxel, another study 
performed by Lolkema et al. (2011) looked at the safety and tolerability of 
combining reovirus with another chemotherapeutic, gemcitabine.60  Pre-clinical 
murine models demonstrated potential efficacy in vivo when treated with the 
combination of reovirus and gemcitabine.61 For the phase I clinical trial, a total of 
16 patients were enrolled between the ages of 36-72, all with various forms of 
advanced cancer.  Gemcitabine was administered at a dose of 1000 mg/m2 on 
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days 1 and 8 of a 21 day cycle.  Reovirus was administered in escalating doses 
on days 1-5 of the cycle.  Doses escalated each cycle as follows: 1 x 109, 3 x 
109, 1 x 1010, and 3 x 1010 TCID50.  However, due to the occurrence of two grade 
3 DLTs, the protocol was amended so that reovirus was only administered on 
day 1 of each cycle, not for 5 consecutive days as previously planned.  Only one 
more DLT greater than grade 2 was encountered following the amended protocol 
and it was at the highest dose of reovirus (3 x 1010 TCID50).  Overall, no MTD 
was found due to the grade 3 DLT which was a rise in liver enzymes (ALT).  The 
patient that experienced this grade 3 rise in ALT was taken off reovirus therapy 
and challenged with gemcitabine monotherapy.  This alone did not produce the 
ALT rise, so it is likely that combination therapy is responsible.  The most 
frequent mild to moderate AEs were pyrexia, nausea, diarrhea, vomiting, chills, 
and increased ALT.  No viral shedding was detected and gemcitabine 
pharmacokinetics, including total system clearance (CL) and volume of 
distribution (Vss), were unaffected by reovirus combination.  Interestingly, it was 
found that the combination therapy attenuates the NARA response relative to 
other previously discussed phase I clinical trials with an average peak much later 
than 2 weeks post reovirus injection.  How and to what extent this is occurring 
will be a major point of study in future research. 
In a study designed to elucidate the benefits of systemic reovirus 
administration, Adair et al. (2012) conducted a phase I clinical trial of reovirus 
monotherapy to patients with colorectal cancer metastatic to the liver and  
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Table 3: Clinical Data for Phase I IV Reovirus Administration Study 
Patient demographics, number of viral infusions administered with a maximum of 
5, and the patients’ ras mutation status is shown.  Na denotes that a sample was 
unavailable for analysis.  Adapted from  Adair, R, et al. (2012).62 
 
Patient Age (years) Sex No. of Viral 
Infusions 
Ras Mutation 
status 
1 74 M 3 12ASP 
2 62 M 5 13ASP, 12VAL 
3 73 M 5 12VAL 
4 66 M 5 12ASP 
5 62 M 5 12CYS 
6 50 F 5 NONE 
7 58 M 4 NONE 
8 65 F 1 NA 
9 70 M 5 NONE 
10 63 M 5 NONE 
    
planned resection.62  All ten patients enrolled in the study were scheduled to 
receive a single cycle of IV reovirus consisting of a 60 min infusion of 1 x 1010 
TCID50 each day for 5 consecutive days.  Due to the fear that flu-like symptoms 
would disrupt the surgery, 2 patients declined to receive the full treatment and 
one patient had an infusion omitted due to clinical concerns over a falling white 
blood cell (WBC) count.  Table 3 illustrates the results.  Similarly to other phase I 
trials, no MTD or DLT were found with the AE being grade 2 or lower.  NARA 
titers all increased over time with most occurring around 2-3 weeks following 
reovirus administration.  Reovirus was shown to preferentially infect tumor cells 
while non-tumor cells were unaffected as confirmed by analyzing liver tissue 
following surgical resection (as part of the planned patient treatment).  It was also 
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shown that replication competent virus could not be found in patient plasma >3 
days following reovirus administration, but was found in peripheral blood 
mononuclear cells (PBMC) despite the presence of NARA present at baseline.  
Additionally, it was found that granulocytes and platelets also carried replication 
competent virus, but not red blood cells (RBCs).  This data suggests that IV 
administration may be more successful than originally hypothesized because it 
appears that PBMCs along with other cells transport the virus systemically and 
can be used to evade to some extent the host NARA response. 
Morris et al. (2012) reported on a dose-escalating study of Reolysin® 
monotherapy when administered as a percutaneous IT injection.63  For this study, 
19 adult patients (age >18) with advanced solid tumors were treated with reovirus 
to determine MTD and DLT.  Doses started at 1 x 107 PFU and escalated to 1 x 
1010 PFU, given once a week.  Injections at 1 x 108 PFU and 1 x 109 PFU were 
then given three times a week once lower dosages were proven safe to test if 
there were any AE with multiple dosages.  All AEs related to reovirus treatment 
were found to be mild; grade 2 or less.  One exception was a case of grade 3 
headaches which was attributed to post-lumbar punctures.  Most common AEs 
included nausea, vomiting, headaches, local erythema, flu-like symptoms, 
diarrhea, and myalgia.  Throughout the study, no DLT and therefore no MTD was 
found.  All patients were tested for NARA response at baseline and post 
treatment and it was found that 7 of 19 had NARA at baseline and all developed 
a peak NARA response ~4 weeks post initial infection.  Efficacy was determined 
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as part of secondary goals and it was found that one patient had complete 
response (CR), two had a partial response (PR), four achieved stabilized disease 
(SD), and ten had partial disease (PD).  The authors also noted that tumors not 
directly injected were unaffected by reovirus in all sampled patients.  This study, 
like those that preceded it, demonstrates that Reolysin® is safe and well 
tolerated, as well as exhibits some of the desired oncolytic properties.   
 
 
C. Phase II Clinical Trials 
 
There are currently 12 recruiting or active phase II clinical trials involving 
Reolysin ® with one trial completed with no published results.66  Of the 13 listed, 
11 involve combination therapies with either chemotherapeutics or radiotherapy.  
This is a significant step in both maximizing reovirus’s oncolytic potential and 
moving toward FDA approval.  Two of the published phase II clinical trials are 
detailed below. 
  Following on the heels of successful phase I clinical trials that 
demonstrated reovirus could be administered safely, Galanis et al. (2012) 
recently reported on a phase II clinical trial of Reolysin® monotherapy to treat 
metastatic melanoma.64  The primary aims of the study were to assess 
Reolysin® efficacy (partial or complete response or stable disease) with 
secondary aims set to determine the effect of baseline NARA levels, viral 
replication in malignant tissue, and overall survival rates in treated patients.  
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Twenty three patients were originally enrolled for this study, but one patient died 
prior to receiving treatment and another was found to be ineligible due to failing 
to meet the minimum metastatic lesion size.  Reolysin® was administered at 3 x 
1010 TCID50 as an IV injection on days 1-5 of a 28 day cycle.  Some severe DLTs 
of grade 3-4 were observed including fatigue, lymphopenia, and hyponatremia.  
Otherwise, AEs were mild with the most common being consistent with previous 
phase I clinical studies and including fatigue, nausea, fever, and anemia.  Over 
the course of the study, treatment was discontinued due to death (1 patient), 
disease progression (19 patients), and increased bleeding from an inguinal site 
(1 patient).  Median time to progression and survival time was 45 and 165 days, 
respectively.  Only 6 patients achieved stable disease for a time period greater 
than eight weeks which did not meet previously defined efficacy levels to 
continue enrolling further patients.  All 21 patients enrolled were positive for the 
presence of NARA at baseline and a maximum NARA response was shown at an 
average of 30 days from the start of treatment.  Biopsies were obtained from 15 
patients, 13 of which contained metastatic tumor.  Of those 13, 2 showed 
reovirus replication.  Those 2 patients also had average or higher than average 
baseline NARA titers and longer than average progression-free survival relative 
to patients in the study, although the small sample size does not allow for 
statistical conclusions.  So while this study failed to demonstrate sufficient 
efficacy levels utilizing Reolysin® as a monotherapy to treat metastatic 
melanoma, it did show that reovirus is capable of infecting and replicating in 
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malignant cells and still holds potential as a viable element of virotherapy when 
used in combination with other anti-cancer agents. 
Another recently completed phase II trial was published by   
Karapanagiotou et al. (2012) which detailed the response to Reolysin® and 
carboplatin/paclitaxel treatment to various head and neck cancers.65  The authors 
looked at the safety and tolerability of the combined treatment as well as its 
efficacy.  Reolysin® was administered IV at a dosage of 3 x 1010 TCID50 on days 
1-5 of a 21 day treatment cycle while carboplatin was given at AUC5 IV on day 1 
and paclitaxel was given at 175 mg IV on day 1 (each chemotherapeutic also on 
a 21 day cycle) for a maximum of 8 cycles.  There were no DLT and most AE 
were < grade 3; no MTD was established.  Patient responses were as follows: 1 
patient had a CR, 6 patients had a PR, 2 patients had clinical responses not able 
to be evaluated by Response Evaluation Criteria in Solid Tumors (RECIST), 9 
patients had SD, and 8 patients had disease progression (DP).     
 
D. Phase III Clinical Trials 
 
Currently, there are no published results of phase III clinical trials involving 
Reolysin®.  There is one phase III trial currently active.66  It involves a 
combination of reovirus therapy and carboplatin/paclitaxel to treat head and neck 
cancers based off of the success of the phase II trial published by 
Karapanagiotou et al. (2012).65  Dosing regiments are identical in the two studies, 
as is the cycle length.  This study, however, is scheduled to proceed until disease 
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progression or death whereas the phase II study stopped after 8 cycles.  The 
primary aim of this study is to assess the overall survival of the estimated 280 
patients enrolled with secondary objectives including establishing safety and 
tolerability measures of the combined treatment and to compare this treatment 
efficacy with treatment regimens in the study population.    
 
Discussion 
 
A. Combination Therapy 
 
 
As demonstrated by the pre-clinical and clinical testing with reovirus, it is 
clear that combination therapy will be necessary to achieve the best results in 
terms of reovirus mediated oncolysis against most forms of cancer.  Reovirus 
monotherapy, for unclear reasons, does not appear to exhibit the same efficacy 
in clinical studies as the pre-clinical studies would suggest.  Potentially, this may 
involve the NARA response or another immune response that is difficult or 
impossible to recreate in animal models.  These responses are likely inhibiting 
reovirus mediated oncolysis in some way.  Applying another agent that is both an 
inherent cancer therapeutic as well as an immunosuppressive agent will likely 
increase reovirus efficacy. 
To date, reovirus has been combined with chemotherapeutics including 
docetaxel, paclitaxel, carboplatin, and gemcitabine among others.57,60,61,65,66  It 
has also been combined with palliative radiotherapy.59  Ongoing studies continue 
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to focus on these combinations given the trends that such therapies are both 
safe and demonstrate an increased efficacy. 
The likely reason behind the increased efficacy in combination in therapies 
is due to the creation of an immunosuppressed environment.  
Chemotherapeutics or other therapies that disrupt the immune responses, 
especially in tumors, allow for increased reovirus mediated oncolysis in those 
tissues.  It is known from studies in SCID mice that reovirus is capable of 
inducing cell death in tumors, but when applied in clinical settings, either the 
NARA response or another element is preventing this from happening.  Based on 
initial clinical studies which show that inducing an immunosuppressed state in 
tumors increases reovirus mediated oncolysis and that in turn adds to the 
efficacy of the chemotherapeutic relative to monotherapy with that drug alone, 
reducing this immune response will likely increase efficacy.  It should be taken 
into consideration however, that a systemic immunosuppressed state could 
potentially be dangerous.  Despite the fact that Reovirus is asymptomatic in 
normal humans, all SCID murine models used to test it eventually die or are 
sacrificed due to reovirus induced disease progression.  It is likely that a least a 
number of AE would present with reovirus therapy in a patient with a 
compromised immune system.   
While it is critical to determine how and why reovirus monotherapy is 
largely unsuccessful in terms of positive disease response, moving forward with 
combination therapies is equally important.  As of yet, there have been no issues 
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with safety and tolerability and the increased efficacy is proof that further studies 
are warranted.    
 
B. Resistance/Immunity 
 
Given the fact that reovirus antibodies are present in a large portion of the 
human population due to exposure at young ages, understanding how resistance 
and immunity work in terms of reovirus mediated oncolysis is an important step in 
employing reovirus as a successful therapeutic.14,24  Researchers must consider 
that a majority of patients will have baseline NARA present.  As with all potential 
viral therapeutics, working around this is important.  
The good news for reovirus is that in terms of resistance and immunity, it 
seems to have little effect over a sustained infection in tumors.  In a majority of 
the clinical testing, a maximum NARA response has been achieved after ~4 
weeks post initial exposure to reovirus then remained constant over the duration 
of continuing treatment.  Despite this response, live and replication competent 
virions have still been isolated from tumor samples indicating that at least in 
tumor cells, reovirus is still able to maintain an infection.  Furthermore, there has 
been no difference in any published study between those that have NARA at 
baseline and those who don’t.  So while overcoming resistance and immunity is a 
challenge to promote efficacy, at least viral infection and replication is intact in 
tumor cells. 
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Additionally, this resistance is likely the reason that reovirus therapy is so 
well tolerated.  Unlike SCID models where reovirus causes death and spreads to 
other tissues, all of the current published clinical studies show little to no viral 
shedding and no virus replication occurring in non-malignant tissues.  Instead, it 
has repeatedly been demonstrated that reovirus infection as well as reovirus 
mediated oncolysis has been limited solely to malignant tissues.   
So while many other viraltherapuetics have considerable difficulty 
overcoming resistance and immunity, reovirus not only is able to maintain an 
infection in an already pre-exposed host, but uses it to enhance its selectivity as 
well as its safety and tolerability.  This is an encouraging aspect of reovirus 
development. 
Another important aspect to combination therapy will be to better 
understand the mechanism behind reovirus mediated oncolysis.  Whether it is via 
reoviurs induced apoptosis or viral immune targeting, or even a combination of 
the two, knowing how reovirus is functioning within tumors to induce oncolysis is 
critical when considering how best to combine therapies.  Pan et al. 2011 
showed some of the potential for this work in demonstrating that p53 stabilization 
can increase reovirus mediated oncolysis.54  However, much more work is 
necessary in this regard because a large portion of the potential behind an 
oncolytic virus is immune targeting which has not been explored in any detail yet 
in a clinical setting.            
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C. Biomarkers 
 
One of the largest concerns for future research is, and will continue to be, 
isolating biomarkers for reovirus therapy.  Previous attempts have so far been 
unsuccessful as reported Twigger et al. (2012).52  Other attempts to identify 
biomarkers are ongoing and at least one phase I clinical study is underway with 
elucidating biomarkers as its primary objective.66   
What identifying biomarkers will allow clinicians to do is employ reovirus 
therapy when it is most advantageous to a patient.  As healthcare across the 
globe trends toward more tailor-made therapy regimens, understanding which 
biomarkers are important to maximizing potential reovirus therapy. 
Additionally, identifying biomarkers is necessary to better understand the 
mechanism behind reovirus mediated oncolysis.  Not only in terms of maximizing 
potential in combination therapies as detailed above, but also to better 
understand which cancers may be targeted for reovirus therapy.  Whether by 
direct reovirus mediated oncolysis or viral immune targeting, if specific cancers 
upregulate certain biomarkers, it would be easier to determine which cancers to 
test reovirus therapy.  Currently, researchers are still using the Ras/PKR model 
to determine which cancers to target, but no significant correlation has been 
drawn between clinical results and this pathway.  Hopefully a better 
understanding of biomarkers will improve pre-clinical models. 
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Conclusion 
 
 It is clear from clinical testing that reovirus has great potential as an 
oncolytic agent.  As Oncolytic Biotech moves forward in pushing Reolysin®, 
which is a non-attenuated, wild type reoviurs (serotype 3 Dearing), it becomes 
increasingly likely that it will be granted FDA approval within the next 2-3 years.  
What is not clear is exactly how its oncolytic effects are occurring.  The ras/PKR 
model that was thought to describe reoviurs tumor selectivity has shown no 
correlation in more recent pre-clinical and clinical data.  Furthermore, it is still 
unclear whether it is reovirus mediated apoptosis or immune targeting that is 
responsible for the oncolytic effects of reovirus therapy.  These are the pressing 
questions that will determine and maximize the efficacy of reovirus as 
viraltherapeutic.   
 Yet, while the mechanisms are unclear, there is overwhelming evidence 
that reovirus will be a successful oncolytic virus as it accounts for a majority of 
the criteria that an ideal oncolytic virus would.  It has been proven that both 
reovirus monotherapy, as well as reovirus therapy combined with a variety of 
chemotherapeutics and radiotherapy, is both safe and well tolerated.  No MTD 
has been established in any of the phase I or phase II clinical trials that have 
been published.  Furthermore, there has been almost no evidence of viral 
shedding or viral replication in non-malignant tissue, indicating that reovirus 
therapy is extremely selective and safe.  Resistance to infection is likely to 
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account for both the safety and selectivity of the drug and baseline NARA levels 
do not seem to impact treatment efficacy.  Continued therapy even against peak 
immune response results in continued infection in malignant tissue.  Systemic 
administration is effective, and according to pre-clinical models, still holds the 
ability to target both primary tumors as well as any potential metastasis.  The 
current data strongly indicates that further study and research are warranted 
towards bringing reovirus to clinical use as an oncolytic virus.       
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